Literature DB >> 33546162

Canonical and Non-Canonical Roles of GRK2 in Lymphocytes.

Jing Cheng1, Peter C Lucas2,3, Linda M McAllister-Lucas1,3.   

Abstract

G protein-coupled receptor kinase 2 (GRK2) is emerging as a key integrative signaling node in a variety of biological processes ranging from cell growth and proliferation to migration and chemotaxis. As such, GRK2 is now implicated as playing a role in the molecular pathogenesis of a broad group of diseases including heart failure, cancer, depression, neurodegenerative disease, and others. In addition to its long-known canonical role in the phosphorylation and desensitization of G protein-coupled receptors (GPCRs), recent studies have shown that GRK2 also modulates a diverse array of other molecular processes via newly identified GRK2 kinase substrates and via a growing number of protein-protein interaction binding partners. GRK2 belongs to the 7-member GRK family. It is a multidomain protein containing a specific N-terminal region (referred to as αN), followed by a regulator of G protein signaling homology (RH) domain, an AGC (Protein kinase A, G, C serine/threonine kinase family) kinase domain, and a C-terminal pleckstrin homology (PH) domain. GPCRs mediate the activity of many regulators of the immune system such as chemokines and leukotrienes, and thus GRK proteins may play key roles in modulating the lymphocyte response to these factors. As one of the predominant GRK family members expressed in immune cells, GRK2's canonical and noncanonical actions play an especially significant role in normal immune cell function as well as in the development and progression of disorders of the immune system. This review summarizes our current state of knowledge of the roles of GRK2 in lymphocytes. We highlight the diverse functions of GRK2 and discuss how ongoing investigation of GRK2 in lymphocytes may inform the development of new therapies for diseases associated with lymphocyte dysregulation.

Entities:  

Keywords:  GPCR; Lymphocyte; cell signaling; lymphoma

Mesh:

Substances:

Year:  2021        PMID: 33546162      PMCID: PMC7913175          DOI: 10.3390/cells10020307

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  66 in total

Review 1.  G protein-coupled receptor kinases: more than just kinases and not only for GPCRs.

Authors:  Eugenia V Gurevich; John J G Tesmer; Arcady Mushegian; Vsevolod V Gurevich
Journal:  Pharmacol Ther       Date:  2011-08-26       Impact factor: 12.310

2.  Eμ/miR-125b transgenic mice develop lethal B-cell malignancies.

Authors:  Y Enomoto; J Kitaura; K Hatakeyama; J Watanuki; T Akasaka; N Kato; M Shimanuki; K Nishimura; M Takahashi; M Taniwaki; C Haferlach; R Siebert; M J S Dyer; N Asou; H Aburatani; H Nakakuma; T Kitamura; T Sonoki
Journal:  Leukemia       Date:  2011-07-08       Impact factor: 11.528

3.  Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function.

Authors:  Raphael E Bonita; Philip W Raake; Nicholas J Otis; J Kurt Chuprun; Talya Spivack; Abhijit Dasgupta; David J Whellan; Paul J Mather; Walter J Koch
Journal:  Clin Transl Sci       Date:  2010-02       Impact factor: 4.689

Review 4.  MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.

Authors:  Inna S Afonina; Lynn Elton; Isabelle Carpentier; Rudi Beyaert
Journal:  FEBS J       Date:  2015-06-10       Impact factor: 5.542

5.  CXCR4 physically associates with the T cell receptor to signal in T cells.

Authors:  Ashok Kumar; Troy D Humphreys; Kimberly N Kremer; Patricia S Bramati; Lavone Bradfield; Contessa E Edgar; Karen E Hedin
Journal:  Immunity       Date:  2006-08       Impact factor: 31.745

6.  Adjuvant arthritis induces down-regulation of G protein-coupled receptor kinases in the immune system.

Authors:  M S Lombardi; A Kavelaars; P M Cobelens; R E Schmidt; M Schedlowski; C J Heijnen
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

7.  Differentially regulated expression of the G-protein-coupled receptor kinases, betaARK and GRK6, during myelomonocytic cell development in vitro.

Authors:  R P Loudon; B Perussia; J L Benovic
Journal:  Blood       Date:  1996-12-15       Impact factor: 22.113

Review 8.  β-arrestins and G protein-coupled receptor trafficking.

Authors:  Xufan Tian; Dong Soo Kang; Jeffrey L Benovic
Journal:  Handb Exp Pharmacol       Date:  2014

9.  Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Authors:  Rami Rahal; Mareike Frick; Rodrigo Romero; Joshua M Korn; Robert Kridel; Fong Chun Chan; Barbara Meissner; Hyo-eun Bhang; Dave Ruddy; Audrey Kauffmann; Ali Farsidjani; Adnan Derti; Daniel Rakiec; Tara Naylor; Estelle Pfister; Steve Kovats; Sunkyu Kim; Kerstin Dietze; Bernd Dörken; Christian Steidl; Alexandar Tzankov; Michael Hummel; John Monahan; Michael P Morrissey; Christine Fritsch; William R Sellers; Vesselina G Cooke; Randy D Gascoyne; Georg Lenz; Frank Stegmeier
Journal:  Nat Med       Date:  2013-12-22       Impact factor: 53.440

10.  G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity.

Authors:  Lucia Garcia-Guerra; Iria Nieto-Vazquez; Rocio Vila-Bedmar; María Jurado-Pueyo; Guillermo Zalba; Javier Díez; Cristina Murga; Sonia Fernández-Veledo; Federico Mayor; Margarita Lorenzo
Journal:  Diabetes       Date:  2010-07-13       Impact factor: 9.461

View more
  3 in total

1.  The Mouse Cytomegalovirus G Protein-Coupled Receptor Homolog, M33, Coordinates Key Features of In Vivo Infection via Distinct Components of Its Signaling Repertoire.

Authors:  Jiawei Ma; Kimberley Bruce; Nicholas Davis-Poynter; Philip G Stevenson; Helen E Farrell
Journal:  J Virol       Date:  2021-12-08       Impact factor: 6.549

Review 2.  The RAF Kinase Inhibitor Protein (RKIP): Good as Tumour Suppressor, Bad for the Heart.

Authors:  Joshua Abd Alla; Ursula Quitterer
Journal:  Cells       Date:  2022-02-14       Impact factor: 6.600

3.  Hydroxychloroquine attenuates autoimmune hepatitis by suppressing the interaction of GRK2 with PI3K in T lymphocytes.

Authors:  Chao Jin; Bei-Bei Gao; Wen-Jing Zhou; Bao-Jing Zhao; Xing Fang; Chun-Lan Yang; Xiao-Hua Wang; Quan Xia; Ting-Ting Liu
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.